|Awarded On||February 19, 2020|
|Title||Doxorubicin-Induced Cardiotoxicity: Defining Blood and Echocardiogram Biomarkers in a Mouse Model and AYA Sarcoma Patients for Evaluating Exercise Interventions|
|Award Mechanism||Individual Investigator Research Awards for Cancer in Children and Adolescents|
|Institution/Organization||The University of Texas M.D. Anderson Cancer Center|
|Principal Investigator/Program Director||Eugenie S Kleinerman|
*Pending contract negotiation
Adolescent and young adult (AYA) sarcoma patients treated with doxorubicin (Dox) are 8.2 times more likely to develop heart failure later in life. We developed an adolescent cardiotoxicity mouse model and showed that exercise decreased acute Dox-induced heart damage and late cardiotoxicity without decreasing tumor efficacy. We wish to define a set of echo and blood biomarkers in patients that can be used to identify patients at risk for cardiotoxicity and for use in a randomized trial to evaluate the clinical effectiveness of exercise in the AYA sarcoma population. The long-term goal is to reduce acute Dox-induced cardiac injury and late cardiomyopathy. Since Dox-induced cardiotoxicity is t...